Detalles de la búsqueda
1.
Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US.
Oncologist
; 29(3): e360-e371, 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38280190
2.
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
N Engl J Med
; 383(23): 2207-2218, 2020 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33264544
3.
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Blood
; 136(1): 93-105, 2020 07 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32202637
4.
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(5): 665-677, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33812497
5.
The C-terminal tails of the mitochondrial transcription factors Mtf1 and TFB2M are part of an autoinhibitory mechanism that regulates DNA binding.
J Biol Chem
; 295(20): 6823-6830, 2020 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32241911
6.
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Blood
; 131(21): 2357-2366, 2018 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29483101
7.
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
Blood
; 129(11): 1469-1479, 2017 03 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-28049639
8.
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
Blood
; 128(15): 1940-1943, 2016 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27503501
9.
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
Blood
; 126(19): 2213-9, 2015 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26337493
10.
Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study.
Br J Haematol
; 194(1): e48-e51, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34114211
11.
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
Blood
; 123(21): 3286-95, 2014 May 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-24659631
12.
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Lancet Oncol
; 16(2): 169-76, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25555420
13.
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Haematologica
; 100(12): 1571-8, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26430171
14.
Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013.
Br J Haematol
; 186(3): e41-e44, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30937889
15.
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.
Br J Haematol
; 186(5): e117-e121, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31090915
16.
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
J Immunol
; 188(7): 3532-41, 2012 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22368276
17.
Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia.
Cancer Med
; 13(2): e6953, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38348963
18.
Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
Leuk Lymphoma
; : 1-11, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696747
19.
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Cancer Discov
; 14(1): 66-75, 2024 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37930156
20.
Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
Leuk Lymphoma
; 64(14): 2286-2295, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37870435